Domů › Nemalobuněčný plicní karcinom › Texas › Irving
Klinické studie Nemalobuněčný plicní karcinom v Irving, TX
22 studií pro Nemalobuněčný plicní karcinom hledá účastníky v lokalitách v Irving a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Probíhá náborFáze 1
- Exelixis Clinical Site #73, Irving
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Probíhá náborFáze 1
- NEXT Dallas, Irving
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Probíhá náborFáze 3
- US Oncology Investigational Product Center (IPC), Irving
- US Oncology Investigational Products Center (IPC), Irving
- US Oncology Investigational Products Center(IPC), Irving
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Probíhá náborFáze 3
- US Oncology Investigational Products Center (IPC), Irving
- US Oncology Investigational Products Center, Irving
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Probíhá náborFáze 3
- US Oncology Research Investigational Products Center, Irving
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Probíhá náborFáze 1/2
- US Oncology Investigational Products Center (IPC), Irving
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Probíhá náborFáze 1/2
- NEXT Oncology - Irving, Irving
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Probíhá náborFáze 1/2
- NEXT Dallas, Irving
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Probíhá náborFáze 1/2
- Next Oncology - Dallas, Irving
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Probíhá náborFáze 2/3
- Local Institution - 007-999, Irving
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Probíhá náborFáze 1/2
- Next Oncology Dallas, Irving
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Probíhá náborFáze 1/2
- NEXT Dallas - Oncology Department, Irving
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Probíhá náborFáze 1/2
- NEXT Dallas, Irving
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Probíhá náborFáze 1
- NEXT Dallas, Irving
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Probíhá náborFáze 1
- US Oncology Investigational Product Center (IPC), Irving
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Probíhá náborFáze 1/2
- NEXT Oncology Dallas, Irving
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Probíhá náborFáze 1
- Next Oncology Dallas /ID# 276254, Irving
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Probíhá náborFáze 1
- NEXT Texas LLC - Dallas, Irving
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Probíhá náborFáze 1
- NEXT Oncology Dallas, Irving
A 2-part Phase 1/2 Open-label Trial on ODM-212
Probíhá náborFáze 1/2
- NEXT Oncology, Irving
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Probíhá náborFáze 1/2
- NEXT, Dallas, Irving
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Probíhá náborFáze 1/2
- NEXT Dallas, Irving
Studie Nemalobuněčný plicní karcinom v jiných městech
- Houston, TX145 studií
- New York City, NY120 studií
- Arlington, VA104 studií
- Nashville, TN97 studií
- Boston, MA90 studií
- Los Angeles, CA87 studií
- St. Louis, MO73 studií
- Chicago, IL61 studií
- Baltimore, MD60 studií
- San Antonio, TX59 studií
- Columbus, OH56 studií
- Washington, DC55 studií
Další studie v Irving
- Rakovina (všechny typy)15 studií
- Kolorektální karcinom13 studií
- Metastatický karcinom11 studií
- Rakovina slinivky břišní7 studií
- Rakovina žaludku7 studií
- Squamózní buněčný karcinom hlavy a krku6 studií
- Rakovina prsu6 studií
- Malobuněčný karcinom plic6 studií
- Rakovina plic6 studií
- Rakovina vaječníků5 studií
- Rakovina endometria4 studií
- Rakovina prostaty4 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.